In this section
@article{Triantafyllou:2024:10.1038/s41575-024-01019-7,
author = {Triantafyllou, E and Gudd, CLC and Possamai, LA},
doi = {10.1038/s41575-024-01019-7},
journal = {Nat Rev Gastroenterol Hepatol},
title = {Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management.},
url = {http://dx.doi.org/10.1038/s41575-024-01019-7},
year = {2024}
}
TY - JOUR
AB - Immunotherapy has changed the treatment landscape for patients with cancer in the past decade. Immune checkpoint inhibitor (ICI)-based therapies have proven effective in a range of malignancies, including liver and gastrointestinal cancers, but they can cause diverse off-target organ toxicities. With the increasingly wider application of these drugs, immune-mediated liver injury from ICIs has become a commonly encountered challenge in clinical hepatology and gastroenterology. In this Review, we discuss the evidence from human and animal studies on the immunological mechanisms of immune-mediated liver injury from ICIs and summarize its clinical features and practical considerations for its management.
AU - Triantafyllou,E
AU - Gudd,CLC
AU - Possamai,LA
DO - 10.1038/s41575-024-01019-7
PY - 2024///
TI - Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management.
T2 - Nat Rev Gastroenterol Hepatol
UR - http://dx.doi.org/10.1038/s41575-024-01019-7
UR - https://www.ncbi.nlm.nih.gov/pubmed/39663461
ER -